CJC-1295

• Community no-DAC pulse protocolrecommended

  Community practice, not from a label or trial. Applies only to the no-DAC form; do not use it for a DAC vial. The source says 2-3 injections a day; the plan logs one.

• FORM 1, NO DAC (Mod GRF 1-29): Community practice, not from a label or trial: 100 mcg per injection, 2-3 times daily, for 8-12 weeks (Peptide Protocol Wiki research protocol; not from a trial).
• FORM 2, WITH DAC: trial only, not a use recommendation. Healthy adults got single subcutaneous doses (four ascending levels) or two to three weekly or biweekly doses; 30 and 60 mcg/kg were the best tolerated (Teichman 2006). No community mg-per-week figure was fetched, so none is encoded and no DAC protocol is offered.
• Do not apply a DAC dose to a no-DAC vial or the reverse: a DAC-sized dose given as a no-DAC schedule would be a large overdose.

Route: Subcutaneous injection (trial: subcutaneous).

Timing: No reliable figure found in the sources; ask your prescriber or supplier.

• Bacteriostatic water is the diluent named by the secondary source, with no volume. The water in the protocol is arithmetic for a readable draw (2000 mcg + 2 mL gives 1000 mcg/mL, so 100 mcg = 10 units), not a sourced instruction.

Secondary source: reconstituted no-DAC solution kept at 2-8 C and used within 14-21 days. Not from a label.

Community: 8-12 week courses, repeatable; no sourced rest period.

Why:

• The sources give no off-cycle length.

• Never draw into the same syringe as another compound; use separate syringes and distinct injection sites.
• As described by the secondary source: no-DAC CJC-1295 is usually paired with ipamorelin, said to give a larger GH release than either alone (no human trial of the pair was fetched). Use separate syringes even for this pair.

Not FDA-approved for any use. The DAC form's developer program ended; vials sold online are unapproved research products of unknown purity.

Common side effects:

• Injection-site reactions (secondary source, no-DAC form).
• The Teichman abstract says no serious adverse reactions were reported and that the drug was relatively well tolerated, especially at 30 or 60 mcg/kg; specific events are not listed in the abstract.
• Growth hormone secretagogues raise GH and IGF-1; people with active cancer, pituitary disease or diabetes should only use them under a prescriber.

Stop and call your prescriber if:

• Swelling of hands or feet, joint pain or numbness in the hands
• Excessive thirst or urination
• Any rash, wheeze or swelling of the face

Labs and monitoring:

• IGF-1 and fasting glucose are the usual checks (inferred from the effect on IGF-I in Teichman 2006; no source lists a schedule).

What sources report this compound changes, or say to check. A record of the evidence, not targets or advice.

• IGF-1Reported changeSmall human study

  DAC form: a single dose raised mean IGF-I 1.5- to 3-fold for 9-11 days; repeat doses kept it above baseline up to 28 days (healthy adults)

  PubMed 16352683: CJC-1295 ascending-dose trials in healthy adults (Teichman 2006)

• PubMed 16352683: Teichman 2006, CJC-1295 (DAC form) ascending-dose trials in healthy adults
• Peptide Protocol Wiki: CJC-1295 (no-DAC research protocol figures; secondary source)